Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.7752W HIGH $16.33
Volume
11.12 K
Value Traded
552.53 K
Short % Float
0.13%
-3.73%Week
+0.74%1 Month
+23.49%3 Month
-10.3%6 Month
-57.18%5 Year
-11.19%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.45 B
EPS (TTM)
2.67
P/E Ratio
5.12
Ent. Value
877.59 M
Total Shares
174.47 M
Float Shares
170.46 M
Insiders
2.30%
Institutions
2.56%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
HCM Catalyst Timeline
Dated clinical, regulatory and corporate events for HUTCHMED (China) Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for HUTCHMED (China) Limited
1072Total events
3Upcoming
287Tier-1 (high impact)
2015 to 2026Coverage
Upcoming catalysts 2
TBD
T2Oral Presentation
Subscribe to view catalyst details
TBD
T1NMPA NDA Approval
Subscribe to view catalyst details
Event history 50
◆Oral PresentationsovleplenibFiledPresentation
ESLIM-02 Phase III data presented at EHA 2026 Congress
warm antibody autoimmune hemolytic anemiasource ↗
▲Primary Endpoint MetsovleplenibFiledClinical Data
ESLIM-02 met primary endpoint: durable response rate 66% vs 15%
warm antibody autoimmune hemolytic anemiasource ↗
●Equity OfferingCorporate
Block admission application for 43,616,756 ordinary shares under 2026 Share Option Scheme
◆Oral PresentationSavolitinibApprovedPresentation
Phase 2 pivotal study of savolitinib in MET-amplified gastric cancer/GEJ adenocarcinoma rapid oral presentation at ASCO 2026
gastric cancer or gastroesophageal junction adenocarcinomasource ↗
◆Poster Presentationfruquintinib+sintilimabApprovedPresentation
Tumor shrinkage and depth of response with fruquintinib in mCRC: Results from FRESCO and FRESCO-2 poster
metastatic colorectal cancersource ↗
◆Poster PresentationSurufatinibApprovedPresentation
Surufatinib + KN046 + chemo as first-line for advanced PDAC: updated results and biomarker analysis poster
pancreatic ductal adenocarcinomasource ↗
◆Poster PresentationSavolitinibApprovedPresentation
Osimertinib + savolitinib in osimertinib-resistant NSCLC with low MET GCN: phase 2 study (publication only)
non-small-cell lung cancersource ↗
▲NMPA NDA ApprovalELUNATEApprovedEx-US Regulatory
NMPA approval for ELUNATE (fruquintinib) in combination with TYVYT (sintilimab) for RCC
locally advanced or metastatic renal cell carcinomasource ↗
▲FDA Filing AcceptedsovleplenibFiledRegulatory Filing
NDA accepted for review by NMPA for wAIHA
warm antibody autoimmune hemolytic anemiasource ↗
▲Priority ReviewsovleplenibFiledRegulatory Filing
Priority review granted by NMPA for wAIHA NDA
warm antibody autoimmune hemolytic anemiasource ↗
◆Poster PresentationHMPL-A580Presentation
Poster presentation of preclinical data for HMPL-A580 at AACR 2026
solid tumorssource ↗
◆Poster PresentationSurufatinibApprovedPresentation
Poster presentation of exploratory Phase II data for surufatinib combined with gemcitabine and nab-paclitaxel at AACR 2026
locally advanced or metastatic pancreatic ductal adenocarcinomasource ↗
▲FDA Filing AcceptedsovleplenibFiledRegulatory Filing
NMPA accepted NDA for review and granted priority review
warm antibody autoimmune hemolytic anemiasource ↗
◆Topline ReadoutORPATHYSApprovedClinical Data
Topline results from SANOVO study expected
non-small cell lung cancer with EGFR mutation and MET overexpressionsource ↗
▲Trial InitiationHMPL-760Trial
Initiation of registrational Phase III trial of HMPL-760 in R/R DLBCL
relapsed/refractory diffuse large B-cell lymphomasource ↗
▲First Patient DosedHMPL-760Trial
First patient dosed in Phase III trial of HMPL-760 plus R-GemOx in R/R DLBCL
relapsed/refractory diffuse large B-cell lymphomasource ↗
▼Drug WithdrawalTAZVERIKDiscontinuedFDA Decision
Voluntary withdrawal of TAZVERIK in the US
follicular lymphoma, epithelioid sarcomasource ↗
▼RecallTAZVERIKDiscontinuedCMC / Inspection
Market withdrawal and product recall in China, Hong Kong, Macau
follicular lymphoma, epithelioid sarcomasource ↗
▼Trial DiscontinuedTAZVERIKDiscontinuedTrial
Discontinuation of tazemetostat treatment in SYMPHONY-1 trial
follicular lymphomasource ↗
▼Drug Safety CommunicationTAZVERIKDiscontinuedSafety
Safety signal: secondary hematologic malignancies in SYMPHONY-1
follicular lymphomasource ↗
●NMPA INDTAZVERIKDiscontinuedEx-US Regulatory
Notification to NMPA, Hong Kong Department of Health, Macau Health Bureau of withdrawal
▲First Patient DosedHMPL-A580Trial
First patient dosed in Phase I/IIa trial of HMPL-A580
unresectable, advanced or metastatic solid tumorssource ↗
▲Trial InitiationHMPL-A580Trial
Global Phase I/IIa trial initiated for HMPL-A580
unresectable, advanced or metastatic solid tumorssource ↗
▲Breakthrough Therapy DesignationsovleplenibFiledDesignation
NMPA granted Breakthrough Therapy Designation for wAIHA
warm antibody autoimmune hemolytic anemiasource ↗
▲FDA Filing AcceptedsovleplenibFiledRegulatory Filing
NMPA accepted resubmitted NDA for ITP and granted priority review
immune thrombocytopeniasource ↗
▲Priority ReviewsovleplenibFiledRegulatory Filing
Priority review granted for ITP NDA resubmission
immune thrombocytopeniasource ↗
▲Full ResultsSavolitinibApprovedClinical Data
Publication of Phase III SACHI results in The Lancet
EGFR mutation-positive non-small cell lung cancer with MET amplificationsource ↗
▲Primary Endpoint MetsovleplenibFiledClinical Data
Phase III part of ESLIM-02 met primary endpoint of durable hemoglobin response rate
warm antibody autoimmune hemolytic anemiasource ↗
▲Trial InitiationSurufatinibApprovedTrial
Initiation of Phase III stage of Phase II/III trial of surufatinib combination for PDAC
metastatic pancreatic ductal adenocarcinomasource ↗
▲Primary Endpoint MetsovleplenibFiledClinical Data
Phase III part of ESLIM-02 met primary endpoint of durable hemoglobin response
warm antibody autoimmune hemolytic anemiasource ↗
●NDA SubmissionsovleplenibFiledRegulatory Filing
NDA submission for sovleplenib in wAIHA to NMPA
warm antibody autoimmune hemolytic anemiasource ↗
▲Other Regulator MilestoneELUNATEApprovedEx-US Regulatory
ELUNATE included in updated NRDL for endometrial cancer and renewed for colorectal cancer
advanced endometrial cancer with pMMR tumors (in combination with TYVYT); metastatic colorectal cancersource ↗
▲Other Regulator MilestoneORPATHYSApprovedEx-US Regulatory
ORPATHYS included in updated NRDL
non-small cell lung cancer with MET exon 14 skipping alterationsource ↗
▲Other Regulator MilestoneSULANDAApprovedEx-US Regulatory
SULANDA renewed in updated NRDL
pancreatic and non-pancreatic neuroendocrine tumorssource ↗
◆Topline ReadoutORPATHYSApprovedClinical Data
Topline results from SAFFRON study expected in first half of 2026
EGFR-mutated, MET-overexpressed and/or amplified, locally advanced or metastatic non-small cell lung cancersource ↗
▲First Patient DosedSurufatinibApprovedTrial
First patient dosed in Phase III part of surufatinib + camrelizumab + nab-paclitaxel + gemcitabine trial for PDAC
metastatic pancreatic ductal adenocarcinomasource ↗
▲FDA Filing AcceptedSavolitinibApprovedRegulatory Filing
NDA accepted and granted priority review by NMPA for savolitinib in gastric cancer
gastric cancer with MET amplificationsource ↗
▲Priority ReviewSavolitinibApprovedRegulatory Filing
Priority review granted by NMPA for savolitinib NDA
gastric cancer with MET amplificationsource ↗
▲Trial InitiationHMPL-A251Trial
Global Phase I clinical development program initiated for HMPL-A251
HER2-expressing solid tumorssource ↗
▲Other Regulator MilestoneTAZVERIKDiscontinuedEx-US Regulatory
TAZVERIK included in first Commercial Insurance Drug List in China
relapsed or refractory follicular lymphoma with EZH2 mutationsource ↗
◆Oral PresentationsovleplenibFiledPresentation
Final analysis of long-term treatment with sovleplenib in adults with chronic primary ITP: ESLIM-01 at ASH 2025
chronic primary immune thrombocytopeniasource ↗
◆Oral PresentationHMPL-A83Presentation
First-in-human dose escalation study of HMPL-A83 in advanced solid tumors at ESMO Asia 2025
advanced solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How HCM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-12-31 | sovleplenib (ESLIM-01) | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B61 / 100
Pipeline Score
$5.0B
Pipeline Value
$2.4B
Commercial Value
Undervalued
Valuation Signal
18
Drugs Scored
7.0x
rNPV / MCap
Top 6%
Small Cap(rank 40 of 658)
Percentile Rank
HUTCHMED (China) Limited holds a solid B-grade pipeline (61/100), with $8.2B risk-adjusted pipeline value, led by Savolitinib in Non-small Cell Lung Cancer (Phase 3), across $147B in total addressable markets.
Commercial products (revenue basis: latest annual revenue in its 20-F, to Dec 2025; product lines from the latest annual filing) Revenue $548.5M x 4.4 = $2.4B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Fruzaqla | $89M | $111M | -19.3% |
| Elunate | $77M | $86M | -10.9% |
| Sulanda | $27M | $49M | -44.8% |
| Orpathys | $19M | $25M | -24.2% |
| Tazverik | $2M | $1M | +157.8% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Savolitinib Small moleculeMarketedNCT04923945 | Non-small Cell Lung Cancer Metastatic | Phase 3 | COMPLETED | 203 | Nov 30, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every HCM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| sovleplenib BreakthroughPriority | warm antibody autoimmune hemolytic anemia | Phase 3 | 2026-06-12 | 66% vs 15%, p<0.0001; 70% vs 22%, p<0.0001; 16% vs 54%, p=0.0001; 11% vs 43%; 50% vs 15%, p=0.003; 3.1 weeks vs 6.3 weeks; 16.1 weeks vs 6.1 weeksRead More | HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress - Sovleplenib demonstrated rapid and durable hemoglobin response with favoRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Cheng Chig FungDirector, Officer (Acting CEO and CFO) | Other | 30,157 30,157 held | $0.00 | 05/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HCM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in HCM for Q2 2026. | ||||
HCM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HCM ranks across every disease it competes in
Competitive Position is a premium feature
See how HCM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHCM News
HCMHUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
HUTCHMED has presented the Phase III ESLIM-02 study results for its investigational drug, sovleplenib, targeting warm antibody autoimmune hemolytic anemia (wAIHA) during the EHA 2026 Congress. The study showed that sovleplenib produced a significantly higher durable response rate and reduced the need for rescue therapies compared to placebo, highlighting its potential to meet urgent treatment needs. In addition, the drug exhibited a favorable safety profile. The positive findings support its New Drug Application, which has been granted priority review in China.
Read more →HCMBlock Admission Application Hong Kong, Shanghai & Florham Park, NJ - Friday, June 5 , 2026: HUTCHMED (China) Limited (" HUTCHMED " or the "Company") (Nasdaq/AIM: HCM; SEHK:13) today announces an application has been made
HUTCHMED (China) Limited has submitted an application for a block admission of 43,616,756 ordinary shares to the London Stock Exchange. This move is part of the company's 2026 Share Option Scheme, which was approved during the annual general meeting on May 12, 2026. The block admission aims to streamline the issuance of shares as options are exercised, with full transparency on the utilization of these shares. The total issued share capital will remain unchanged at 872,335,120 ordinary shares following this application.
Read more →HCMHUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting Hong Kong, Shanghai & Florham Park, NJ - Fri day
HUTCHMED (HCM) announced the presentation of new clinical data at the 2026 ASCO Annual Meeting, scheduled for May 29 to June 2, 2026, in Chicago. Notably, a pivotal Phase II study of savolitinib in patients with MET-amplified gastric cancer demonstrated a significant objective response rate (ORR) of 32.3%. Additionally, various studies on fruquintinib and other compounds will also be presented, indicating a broad scope of ongoing research and development by the company.
Read more →HCMHUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE (Fruquintinib) in Combination with TYVYT (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
HUTCHMED and Innovent have received NMPA approval for their drug combination ELUNATE and TYVYT to treat patients with locally advanced or metastatic renal cell carcinoma. This approval follows positive results from the FRUSICA-2 trial, which showed that the combination significantly reduces the risk of disease progression, achieving a median progression-free survival of 22.2 months. The treatment aims to address the unmet medical needs of patients who have failed prior therapies. This marks a notable advancement in therapy for patients with challenging cancer types in China.
Read more →HCMAnnual General Meeting held on May 12, 2026 - Poll Results
HUTCHMED (China) Limited announced the successful results of its Annual General Meeting held on May 12, 2026, where all ordinary and special resolutions were passed. The resolutions included the approval of audited financial statements and the re-election of several directors, with overwhelming support from shareholders. Notably, the company also adopted a new Share Option Scheme for 2026. This meeting reflects strong shareholder confidence in the company's governance and strategic direction.
Read more →HCMTotal Voting Rights Hong Kong, Shanghai & Florham Park, NJ - Thursday
HUTCHMED (China) Limited has reported an update on its issued share capital as of April 30, 2026. The total number of ordinary shares stands at 872,335,120, each carrying one voting right. This figure serves as a benchmark for shareholders to assess their notification obligations under the Financial Conduct Authority's regulations. Additionally, it specifies the equivalence of ordinary shares in terms of depositary interests and American depositary shares traded on different exchanges.
Read more →HCMHUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
HUTCHMED has received acceptance for its New Drug Application (NDA) for sovleplenib by the China National Medical Products Administration (NMPA), granted priority review and breakthrough designation. This treatment aims to address warm antibody autoimmune hemolytic anemia (wAIHA), an autoimmune disorder with limited existing therapies. The NDA is bolstered by promising clinical data demonstrating significant hemoglobin response rates. Furthermore, the Phase III trial results are set to be presented at the upcoming European Hematology Association Congress 2026.
Read more →HCMHUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
HUTCHMED (HCM) has announced that it will present new and updated data at the AACR Annual Meeting 2026, showcasing several studies including the first-in-class HMPL-A580, an antibody-targeted therapy conjugate. This compound demonstrated robust anti-tumor effects and selectivity against cancer cell lines expressing EGFR. Additionally, updated results from a multicenter trial of surufatinib combined with other therapeutics will be highlighted. These presentations underscore HUTCHMED's commitment to advancing precision oncology through innovative therapies.
Read more →HCM2025 Annual Report and Notice of Annual General
HUTCHMED (China) Limited announced that its 2025 Annual Report and related AGM materials will be posted on April 10, 2026, for shareholders opting for printed versions. The upcoming 2026 Annual General Meeting is scheduled for May 12, 2026, at the Harbour Grand Kowloon in Hong Kong, available through an electronic platform for those unable to attend in person. HUTCHMED focuses on developing targeted therapies and immunotherapies for cancer and immunological diseases, with its products already marketed in various regions.
Read more →HCMHUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
HUTCHMED has initiated a Phase III trial of its investigational drug HMPL-760 in combination with R-GemOx for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in China. The trial, which started on March 20, 2026, aims to evaluate efficacy and safety in approximately 240 patients. HMPL-760 has shown promise in prior studies and targets Bruton's tyrosine kinase (BTK), a key factor in DLBCL treatment resistance. Although progress has been made, future outcomes are subject to various clinical and regulatory challenges.
Read more →HCMVesting of awards under the Long Term Incentive Plan
HUTCHMED (China) Limited announced the vesting of non-performance based awards under its Long Term Incentive Plan for Dr. Weiguo Su, the Executive Director, CEO, and Chief Scientific Officer. The awards, granted on March 13, 2024, were vested on March 13, 2026. This notification fulfills the requirements of the UK Market Abuse Regulation.
Read more →HCMVesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Wednesday
HUTCHMED (China) Limited has announced the successful vesting of awards under its Long Term Incentive Plan for two executive directors, Dr. Weiguo Su and Mr. Johnny Cheng, on March 10, 2026. The awards, which included a total of 726,317 ordinary shares, were granted on June 5, 2023. This vesting followed the company's announcement of its 2025 annual results on March 5, 2026, and serves to align the interests of the executive team with those of the shareholders.
Read more →HCMHUTCHMED Announces Update on Licensed Oncology Product TAZVERIK in China
HUTCHMED has announced a market withdrawal and product recall of TAZVERIK in China due to Ipsen's decision to withdraw the oncology drug in the US over safety concerns regarding secondary hematologic malignancies. As a result, HUTCHMED will discontinue all active clinical trials involving tazemetostat and has informed healthcare authorities and professionals about the situation. Patients currently receiving tazemetostat are urged to consult with their physicians regarding alternative treatment options, while the company continues to cooperate with regulatory authorities on the next steps for the withdrawal.
Read more →HCMIntended retirement of Independent Non-executive Director and changes of composition of board committees
HUTCHMED (China) Limited announced the upcoming retirement of Professor Mok Shu Kam, Tony, an Independent Non-executive Director, who will not seek re-election at the annual general meeting on May 12, 2026. Professor Mok's tenure will conclude, marking nearly nine years of service, during which he played a significant role in strengthening the Board and guiding the Company's scientific efforts. Alongside his retirement, there will be changes to the composition of board committees pending re-elections at the AGM. The Board expressed gratitude for Professor Mok's contributions, emphasizing the impact of his leadership on HUTCHMED’s strategy.
Read more →HCMHUTCHMED Reports 2025 Full Year Results and - Geographic expansion driving ex-China
HUTCHMED reported its 2025 full-year results showcasing a net income of $457 million, attributed to its profitable core operations and geographic expansion beyond China. The company has seen substantial growth in sales of its key product, FRUZAQLA, while also mentioning challenges such as a 21% decline in oncology product revenues due to market headwinds. HUTCHMED expressed optimism for future growth supported by a robust pipeline and a strong financial position with $1.4 billion in cash, positioning them well for continued investment in innovative drug development.
Read more →HCMHUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors - Second clinical candidate from HUTCHMED's next-generation ATTC platform - - Leveraging synergy thro
HUTCHMED has initiated a global Phase I/IIa clinical trial for HMPL-A580, its second Antibody-Targeted Therapy Conjugate (ATTC), targeting advanced solid tumors. This candidate aims to synergize PAM pathway inhibition with anti-EGFR therapy, employing a unique link between a selective PI3K/PIKK inhibitor and an anti-EGFR antibody. The trial, which has begun dosing patients in China and the US, will assess safety, pharmacokinetics, and preliminary efficacy. HUTCHMED's ATTC platform is positioned as a novel approach to enhance targeted therapy responses.
Read more →HCMHUTCHMED to Announce 2025 Final Results
HUTCHMED (China) Limited has announced that it will present its final results for the year ended December 31, 2025, on March 5, 2026. The company will conduct two webcasts, one in English and another in Chinese, to discuss these results with analysts and investors. The webcasts will allow for Q&A sessions and will be accessible via the company's website. A replay of the presentations will be provided shortly after the events.
Read more →HCMHUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
HUTCHMED announced that the Phase III trial results of savolitinib and osimertinib were published in The Lancet, confirming significant efficacy in treating advanced non-small cell lung cancer (NSCLC) with MET amplification. The combination therapy demonstrated substantial improvements in progression-free survival compared to chemotherapy, with a median of 8.2 months. Regulatory approval for this treatment was granted in China in June 2025. The results highlight a new strategy in addressing resistance mechanisms in EGFR-mutated NSCLC patients.
Read more →HCM▲ +6.6%on this news
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China - Delivers rapid, durable responses in wAIHA, the more c
HUTCHMED has reported positive topline results from the Phase III portion of the ESLIM-02 trial for its drug sovleplenib, targeting warm antibody autoimmune hemolytic anemia (wAIHA). The study, conducted in China, met its primary endpoint by demonstrating a durable hemoglobin response in treated patients. This investigational treatment may represent a significant advance for patients with limited options after failing standard therapies. The full study results will be presented at an upcoming scientific conference, with plans for a New Drug Application submission to the China NMPA in the first half of 2026.
Read more →HCMHUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Na ve Pancreatic Ductal Adenocarcinoma Hong Kong, Shanghai & Florham Park, NJ - Monda
HUTCHMED has commenced the Phase III stage of its clinical trial investigating a combination treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). This trial will evaluate the efficacy and safety of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine against standard treatment. Enrollment aims to expand the trial to approximately 400 additional patients following initial promising results in the Phase II segment, which demonstrated better progression-free survival rates with the experimental regimen. However, PDAC retains a notably low survival rate, highlighting the urgency of effective treatments.
Read more →About HUTCHMED (China) Limited
BIOPHARMAWATCH ELITE PLUS
Trade the next HCM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime